RenovoRx (RNXT) Q2 2026 Earnings Call Transcript
RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.
How this was made
The 30-second read
Why it matters
Traders can update RNXT’s near-to-mid-term revenue trajectory and clinical timeline risk after the company confirmed Phase III enrollment closure, provided event progress, and raised FY2026 revenue guidance while reiterating a breakeven target in Q4 2027.
Market read
The call is a multi-metric update: revenue growth and guidance, commercial center expansion, and Phase III enrollment and event progress, all of which can shift valuation expectations.
What to watch
Cash fell from $12.4M to $9.5M QoQ, and gross margin guidance is only modestly higher (84% to 85% range), so execution must improve without relying on large margin expansion.
Background
RenovoRx is commercializing its RenovaCath device and running the Phase III TIGeR-PaC trial in pancreatic cancer, with a stated plan to transition clinical sites to commercial use.
Ticker impact
RenovoRx reported record Q2 revenue of $909,000, raised FY2026 guidance to $3.75M-$4.25M, and confirmed Phase III TIGeR-PaC enrollment completion.
Likely positive bias for RNXT as raised guidance and Phase III enrollment completion reduce key execution uncertainties, though dilution/cash burn risk remains.
The article discloses multiple new, decision-relevant datapoints: raised FY2026 revenue range, cash runway into H2 2027, and Phase III enrollment closure with event counts. However, it does not provide final clinical efficacy results, limiting upside conviction.
Market effects
Reinforces investor appetite for device-enabled oncology delivery platforms with progressing Phase III programs and expanding commercial adoption.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited, as the disclosed milestones are company-specific and US FDA-cleared device/US trial execution.
Counterpoint
Raised revenue guidance may still be small in absolute dollars, and the company’s path to breakeven depends on scaling center activations and repeat ordering.
Key entities
- companyRenovoRx, Inc.
RNXT reported record Q2 revenue, raised FY2026 guidance, and confirmed Phase III TIGeR-PaC enrollment completion.
- clinical_trialTIGeR-PaC
Phase III trial; enrollment closed Aug. 7 and 78 of 86 survival events observed as of Aug. 11, 2026.
- productRenovaCath
FDA-cleared drug-delivery device; management cited 900+ successful procedures and expanding commercial center network.
